bioMérieux's serology tests to detect antibodies in people exposed to SARS-CoV-2

In its media release, BioMérieux updates the public on its serology tests to detect antibodies in people who have been exposed to SARS-CoV-2

bioMérieux, a world leader in the field of in vitro diagnostics, today announced the CE marking of VIDAS® anti-SARS-CoV-2 serology tests to detect antibodies in people who have been exposed to SARS-CoV-2 which causes the COVID-19 disease.

VIDAS® anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG are used to measure the presence of antibodies in people who have been infected with SARS-CoV-2. In this context, clinical specificity is particularly important to ensure that testing of uninfected individuals consistently delivers a negative result. Both VIDAS® anti-SARS-CoV-2 IgM and anti-SARS-CoV-2 IgG provide results in less than 30 minutes and demonstrate excellent performance on a large number of clinical specimens, with 99.4% and 99,9% specificity, respectively.

Access the release.

Share this page Share on FacebookShare on TwitterShare on Linkedin
Close

COVID-19

#StaySafeAtHome
#WorkFromHome
#TakeCare